Rapport Therapeutics Stock

rapportrx.comHealthcare / Healthcare softwareFounded: 2022Funding to Date: $250.18MM

Rapport Therapeutics is dedicated to crafting precision medicines tailored to the complexity of the human brain, marking a significant stride in the field of neuro medicines. Emphasizing a scientific partnership approach, they deliver revolutionary, relentless, and precise treatments. Their mission is to address neurological complexities with unmatched accuracy, leveraging cutting-edge research and development to create therapies that accurately match the nuanced needs of individuals. ​​

Register To Buy and Sell Private Company Shares

For more details on financing and valuation of private companies similar to Rapport Therapeutics before its IPO, register or login today.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value

Powered by Forge Data

Access valuation and stock price for companies like Rapport Therapeutics before its IPO.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Access Stock Price

Animation displayed is not current and securities are shown for illustrative purposes only.

Rapport Therapeutics’ stock FAQs


Can you buy Rapport Therapeutics’ stock?

You can no longer buy Rapport Therapeutics’ stock on a secondary marketplace as this company is no longer private. If you are interested in buying stock of other private companies, learn more about how to invest in the private market or register today to get started.

How to buy Rapport Therapeutics’ stock?

To invest in a private company like Rapport Therapeutics’ through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)
  1. Create a free account to access Forge's marketplace.
  2. Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
  3. Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.

Can you sell Rapport Therapeutics’ stock?

You can no longer sell stock of Rapport Therapeutics on Forge as this company is no longer private. However, if you own stock of a private company, Forge may help you sell it in a way that works for you and the company. Learn more or register with us today to get started.

How to sell Rapport Therapeutics’ stock?

If you hold private company shares of Rapport Therapeutics’ - whether as an employee or an early investor - Forge can help you sell them.
  1. Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
  2. Indicate your interest to sell your Rapport Therapeutics’ on our platform.
  3. Work with your dedicated Private Market Specialist who'll help guide you through every step of the transaction.

Is Rapport Therapeutics’ a public company?

No, Rapport Therapeutics’ is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.

What is Rapport Therapeutics’ stock ticker symbol?

The ticker symbol of Rapport Therapeutics is RAPP.

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.


CNS disorder biotech Rapport Therapeutics sets terms for $136 million IPO

Rapport is setting the stage for a potential public offering.

J&J-backed startup Rapport files for US IPO

Rapport Therapeutics announced its recent IPO filing.
Updated on: Jul 23, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.